Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 06, 2004. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and does not contain a full financial statement or operational review.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions related to employee benefit plans.
Material Changes
The filing details two specific transactions regarding directors' interests:
- US Retirement Savings Plan: On December 2, 2004, the number of Ordinary Share ADRs held by the GlaxoSmithKline US Retirement Savings Plan decreased from 18,843,565 to 18,804,786 due to fund movements. The average price was $42.65. Directors Dr. J P Garnier and Dr. T Yamada are potentially interested in these shares as beneficiaries.
- Employee Share Option Plan: On December 3, 2004, Abacus (GSK) Trustees Limited transferred 8,384 Ordinary Shares from the GlaxoSmithKline Employee Trust to participants in the SmithKline Beecham Employee Share Option Plan 1991. Directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe are potentially interested in these shares.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a disclosure of shareholding changes.
Key Facts for Investor Verification
- Verify the total number of shares held by directors through discretionary employee trusts versus direct holdings.
- Confirm the impact of the December 2, 2004 fund movement on the US Retirement Savings Plan's total ADR position.
- Review the specific terms of the SmithKline Beecham Employee Share Option Plan 1991 regarding the transfer of 8,384 shares.